In the context of health research, both observational studies and clinical trials are crucial for understanding disease processes, patient outcomes, and the safety and efficacy of treatments. However, due to varying regulatory requirements and standards, the archiving requirements for these types of studies are distinct. Here are some of the key differences:
[1] Regulations and Guidelines: Clinical trials as governed by a global set of ethical and scientific standards, such as ICH GCP. These standards are then adopted into law in different regions, say for instance, through the Regulation EU/536/2014, and 21 CFR 312 in the US. These rules are clear about how to manage, store, and archive data and require specific documents to prove the integrity of the trial data. They also set out how long these crucial documents should be kept (e.g., at least 25 years).
On the flip side, observational studies aren’t governed by such unified requirements when it comes to document retention and archiving. They still follow ethical guidelines and good practice principles like the Declaration of Helsinki, ISPE GPP, and STROBE guidelines, but these may not give you exact retention times or archiving mechanisms.
[2] Data Collection and Confidentiality: Clinical trials are data-rich; they collect a large amount of confidential and sensitive patient data. Regular sponsor audits and regulatory inspections mean they need to keep robust records. Observational studies, while they also handle sensitive data, usually don’t interact with patients as much and don’t face as many regulatory inspections. So, they’ve traditionally not had to maintain as meticulous records.
[3] Data Accessibility: Clinical trial data is often more restricted in terms of who can access it and how it can be shared. This is due to both regulatory needs and commercial interests. Observational data, though, is often used for big-picture disease studies, and it’s usually designed to be more shareable – as long as it’s anonymized and ethical procedures are followed.
It’s important to remember that what I’ve explained are general patterns. The exact requirements can change based on region, the type of data you’re dealing with, and even who’s funding your work. If you need specific guidance, don’t hesitate to reach out to an expert or regulatory authority in your area.
Share this story...
Real World Evidence (RWE) 101 – Ethical Imperatives (CIOMS 2023)
RWE 101 - Ethical Imperatives (CIOMS 2023) Informed decision making with patients typically relies on evidence from clinical trials that describe the likely benefits and toxicities. However, patients treated [...]
Real World Evidence (RWE) 101 – Ethical Imperatives
RWE 101 - Ethical Imperatives Real-world evidence (RWE) refers to the clinical evidence regarding the usage and potential benefits or risks of a product derived from analysis of real-world [...]
Real World Evidence (RWE) 101 – The Importance of Intent
RWE 101 - The Importance of Intent Real-world evidence (RWE) is the clinical evidence about the usage and potential benefits or risks of a product derived from the analysis [...]
Real World Evidence (RWE) 101 – Inspections
RWE 101 - Inspections Real-World Evidence (RWE) can include data from sources such as electronic health records (EHRs), insurance claims and billing activities, patient registries, patient-generated data, and data [...]
Real World Evidence (RWE) 101 – Audits
RWE 101 - Audits A quality assurance auditor in the context of a real-world evidence (RWE) study has several responsibilities, key among them ensuring that all facets of the [...]
Real World Evidence (RWE) 101 – Compliance Maps
RWE 101 - Compliance Maps In the context of multi-country Real-World Evidence (RWE) studies, "Regulatory Compliance Maps" are essentially a detailed representation of the diverse regulatory requirements specific to [...]







